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Abstract: Statins became available for the treatment of hypercholesterolemia in 1987. Multiple, 
well-designed, placebo-controlled, double-blind studies revealed that each 1% reduction in 
serum cholesterol level was associated with about 1% reduction in risk of cardiovascular events. 
Low-density lipoprotein (LDL) cholesterol reduction to less than 78 mg/dL may be associated 
with reduction of atheroma burden. Patients with high levels of high speciﬁ  city C-reactive protein 
and having LDL cholesterol less than 3.4 mmol/L (130 mg/dL) in primary prevention settings 
beneﬁ  ted from aggressive LDL cholesterol reduction with rosuvastatin over a 2-year period. 
However, in real life practice, about half of patients who are prescribed statins discontinue the 
medication by the end of the year. Medication adherence is lower in younger patients, women, 
and absence of known coronary heart disease. Personal features of the prescribing physician 
and dispensing pharmacies also affect patients’ compliance. More studies are needed to evaluate 
if  “compliance packets” would beneﬁ  t patients in a real life situation.
Keywords: cardiovascular risk, statin, goal attainment, primary prevention, secondary 
prevention
Introduction
Coronary artery disease (CAD) is the most common cause of death in the developed 
countries in both men and women. Billions of dollars are spent on research and 
development of new therapies as well for the therapy itself to prevent both the risk 
of recurrent cardiovascular (CVD) events (secondary prevention) as well as pre-
venting the ﬁ  rstt event (primary prevention).1,2 Ever since the connection between 
cholesterol levels and risk for CAD was established, the goal of lowering total 
cholesterol and low-density lipoprotein (LDL) cholesterol became a very important 
health issue.3
Based on new evidence,4–6 targeted goals for cholesterol lowering have been pro-
gressively moved downward to lower levels, and the current modiﬁ  ed recommendations 
by United States National Cholesterol Education Program (NCEP) Adult Treatment 
Panel III7 include the following:
1.  LDL cholesterol less than 2.6 mmol/L (100 mg/dL) for patients with high risk 
(10-year risk more than 20%) for the development of cardiovascular event.
2.  LDL cholesterol less than 1.8 mmol/L (70 mg/dL) in very high risk populations 
with previous history of coronary heart disease (CHD) or equivalents (such as 
diabetes mellitus, carotid artery disease, peripheral artery disease).
3.  The recommended goal is less than 3.4 mmol/L (130 mg/dL) for patients with 
moderately high risk (2+ risk factors or 10 year risk 10%–20%) and less than 
2.6 mmol/L (100 mg/dL) is optional.
4.  In patients with 1 or less risk factors and less than 10% risk of development of 
CVD event over the next 10 year the recommended goal is LDL cholesterol less 
than 4.14 mmol/L (160 mg/dL).7Vascular Health and Risk Management 2009:5 370
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The Fourth Joint Task Force of the European Society 
of Cardiology and other societies on cardiovascular disease 
prevention in clinical practice established the following goals 
for LDL cholesterol:
1.  Less than 3 mmol/L (115 mg/dL) for general population.
2.  Less than 2.5 mmol/L (100 mg/dL) in high risk patients 
and less than 2.0 mmol/L (80 mg/dL) if feasible.8,9
Statins and LDL cholesterol 
level reduction
Lovastatin, the ﬁ  rst inhibitor of the rate-limiting enzyme in 
the cholesterol biosynthetic pathway, 3-hydroxy-3-methyl-
glutaryl-CoA (HMG-CoA) reductase, was approved by the 
FDA in 1987 for the treatment of hyperlipidemia.10 Since 
then 7 other statins became available, though cerivastatin 
was withdrawn from the market in 2001 because of the 
high rate of serious myopathic side-effects. The mechanism 
of action of statins includes the reduction of intracellular 
mevalonate synthesis, the cholesterol precursor. This leads to 
decrease of regulatory sterol pool. That causes upregulation 
of LDL receptors and thus increases the uptake of LDL and 
very low-density lipoprotein (VLDL) particles from blood. 
Statins are also known to reduce the production of Apo B 
containing particles by the liver, though this is clearly the 
secondary mechanism.10
Seven statins are currently available: lovastatin, 
ﬂ  uvastatin, pravastatin, simvastatin, atorvastatin, pitavastatin 
and rosuvastatin. Pitavastatin was approved in Japan in 
July 2003 and later in South Korea and India. It is expected 
to be available in several European countries from the 
second half 2010.11 Rosuvastatin is the latest addition to 
the HMG-CoA reductase inhibitor family and became 
available in the US in 2003.12 It has unique properties and, 
unlike other statins (excepting pravastatin), is hydrophilic. 
Rosuvastatin, pitavastatin and ﬂ  uvastatin are metabolized 
through cytochrome P450 2C9, and have less drug–drug 
interaction than other statins that are metabolized through 
the cytochrome P450 3A4 system along with many other 
commonly used drugs.13 Overall, pravastatin, pitavastatin 
and rosuvastatin undergo little metabolism.14
Rosuvastatin is the most potent statin currently approved 
in the US and Europe, and is associated with about 50% 
LDL cholesterol reduction at a 10 mg daily dose. Efﬁ  cacy 
and safety of rosuvastatin versus atorvastatin, simvastatin, 
and pravastatin across doses was studied in the STELLAR 
study.8 STELLAR was a head-to-head study of 2268 adults 
with LDL cholesterol between 160 and 250 mg/dL. The 
STELLAR trial evaluated the effect of different doses of 
rosuvastatin (10–20 and 40 mg/day), atorvastatin, simvastatin 
(10, 20, 40 or 80 mg/day), and pravastatin (10, 20 or 
40 mg/day).8 Patients on rosuvastatin 40 mg/day achieved 
up to 55% of LDL cholesterol reduction, on maximal 
dose of atorvastatin (80 mg/day) 51.1%, on simvastatin 
(80 mg/day) 45.8%, and on pravastatin (40 mg/day) 29.7%. 
Moreover, patients on rosuvastatin had signiﬁ  cant increments 
in high-density lipoprotein (HDL) cholesterol compared 
to other statins (Table 1).8 A meta-analysis of 164 short 
studies conﬁ  rmed the STELLAR ﬁ  ndings.15 The efﬁ  cacy of 
different statins in a dose-dependent manner on lowering 
LDL cholesterol has been evaluated. The meta-analysis 
showed that 40 mg of ﬂ  uvastatin reduced LDL cholesterol 
on average by 27%, pravastatin by 29%, lovastatin and 
simvastatin by 37%, atorvastatin by 49%, and rosuvastatin 
by 53%. Thus rosuvastatin was the most efﬁ  cacious of all the 
statins, followed by atorvastatin and simvastatin Table 1).15 
The STELLAR study8 also revealed that the Adult Treatment 
Panel III LDL cholesterol goal was achieved by 82% to 89% 
of patients treated with rosuvastatin 10 to 40 mg compared 
with 69% to 85% of patients treated with atorvastatin 10 to 
80 mg. The European LDL cholesterol goal of 3.0 mmol/L 
Table 1 Low-density lipoprotein (LDL) reduction/ATP III goal achievement in comparison study (STELLAR trial), meta-analysis and in a 
real life (REALITY) study.
Pravastatin Lovastatin Fluvastatin Simvastatin Atorvastatin Rosuvastatin
LDL reduction on 40 mg/day (meta-analysis)15 29% 37% 27% 37% 49% 53%
LDL reduction (%) STELLAR8 40 mg/day 
80 mg/day
29.7%* 
NA
NA 
NA
NA 
NA
38.8%* 
45.8%*
47.8%* 
51.1%*
55% 
NA
Attainment of ATP III goals (STELLAR) 
(% of patients)8 on maximal dose
54%* NA NA 82% 85% 89%
Real life ATP III goal attainment REALITY 
study (% of patients)57
10 mg 35.9% 
20 mg 37.9% 
40 mg 38.9% 
80 mg NA
20.0% 
15.9% 
5.6% 
NA
NA 
33.0% 
34.3% 
28.6%
52.5% 
45.5% 
29.9% 
11.4%
56.4% 
40.0 % 
27.2% 
6.7%
NA
*Statistically signiﬁ  cant compared to the rosuvastatin 40 mg PPO daily; p  0.002 is statistically signiﬁ  cant.8Vascular Health and Risk Management 2009:5 371
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(115 mg/dL) was achieved by 79% to 92% in rosuvastatin 
groups compared with 52% to 81% in atorvastatin groups 
(Table 1).
A possible explanation for better LDL cholesterol 
lowering efﬁ  cacy of rosuvastatin and atorvastatin may lie 
in their pharmacodynamic properties. Their half-life is 
much longer than that of the other statins (19 and 14 hours 
respectively vs 1.5–3 hours for the rest).13
The efficacy of 2 mg daily of pitavastatin has been 
compared to 20 mg of simvastatin daily in a prospective, 
randomized, open-label phase III trial.16 The percent 
LDL cholesterol reduction achieved was comparable in 
both groups (mean [SD], 38.2% [11.6%] for the pitavas-
tatin group vs 39.4% [12.9%] for the simvastatin group 
[p = 0.648]).16 In another study,17 the efﬁ  cacy of 2 mg of 
pitavastatin (n = 88) was evaluated in a 52-week, random-
ized, open-label, parallel-group study in comparison with 
10 mg daily of atorvastatin (n = 85). Atorvastatin 10 mg/day 
lowered LDL cholesterol more signiﬁ  cantly than pitavastatin 
(−40.1 vs −33.0, respectively; p = 0.002), but effects on HDL 
were more pronounced in the pitavastatin group (8.2% vs 
2.9% increase, respectively; p = 0.031).17
CVD risk reduction
Multiple, well-designed, double-blind, placebo-controlled 
studies have documented signiﬁ  cant cardiovascular risk 
reduction in patients in primary and secondary prevention 
groups by lowering of LDL cholesterol by statins.4–6,18–25 
Meta-analysis of 19 studies (10 of them statin trials)26 in 
81,859 participants with stable CHD showed that each 1% 
reduction in serum cholesterol level has been associated with 
about 1% reduction in risk of CHD. The ﬁ  ndings were consis-
tent in statin and non-statin trials, suggesting that there was no 
additional pleiotropic effect from statin therapy beyond LDL 
cholesterol reduction. The ﬁ  ndings did not differ for primary 
or secondary prevention.26,27 More recent meta-analysis of 
14 statin (n = 100,827), 7 ﬁ  brates (n = 21,647), and 6 niacin 
(n = 4445) trials, and 1 trial each of a bile acid sequestrant 
(n = 3806), diet (n = 458), and ileal bypass surgery (n = 838) 
detected the same relationship.28
There is a wealth of evidence that statins have not only 
cholesterol lowering properties, but anti-inflammatory 
action and direct effects on endothelial function. One study 
evaluated the effect of statins on global inﬂ  ammatory gene 
expression in vivo and found that some, but not most, were 
moderately downregulated by rosuvastatin and simvastatin. 
This result suggested that most anti-inﬂ  ammatory effects of 
statins are exerted at the post-transcriptional level.29 The study 
by Shioto30 suggests that many statin pleiotropic effects are 
through the activation of AKT-mediated pathways. This 
includes an increase of eNOS activity via heat-shock protein 
90 (HSP 90), which increases nitric oxide production, protein 
synthesis and cell proliferation via mammalian target of 
rapamycin (mTOR) pathway and activation of S6K. Statins 
affect the cytoskeletal proteins that play an important role 
in cell migration.30 The role of statins is expanding due to 
their multiple pleiotropic effects. Some reports suggest the 
effectiveness of statins in improving bone mineral density and 
healing after osteoporotic fractures,31 and use for systemic 
sclerosis and Raynaud’s phenomenon,32 rheumatoid arthritis, 
and other conditions including Alzheimer’s disease and even 
cancers.33
With sustained reductions of total and LDL choles-
terol levels over time, the risk of CVD mortality and CVD 
events declines. Meta-analysis of 58 trials (76,359 subjects 
on different types of therapy and 71,962 controls) showed 
that for each LDL cholesterol reduction of 1.0 mmol/L, the 
risk of CVD events was reduced by 11% in the ﬁ  rst year of 
treatment, 24% in the second year, 33% in years 3 to 5, and 
by 36% thereafter (p  0.001 for trend). There was again 
no difference in the mode of cholesterol reduction. Half 
the patients had prior CVD and there was no difference in 
reported improvement between the two groups.15
A meta-analysis has also been used to assess effects of 
statin therapy (alone) in primary prevention (cardiovascular 
mortality and morbidity), and included 20 studies with more 
than 65,000 subjects.34 The relative risk (RR) of all cause 
mortality was 0.93 (95% CI 0.87–0.99, p = 0.03); of CVD 
mortality 0.89 (95% CI 0.81–0.98, p = 0.01); of myocardial 
infarction (MI)-attributed mortality 0.46 (95% CA 0.26–0.79, 
p = 0.005) and acute MI 0.77 (95% CI 0.63–0.95, p = 0.01).24 
However, this meta-analysis did not included studies with 
simvastatin, pitavastatin or rosuvastatin, since at the time of 
publication no trials had met the inclusion criteria.
Recently the results of Justiﬁ  cation for the Use of Statins 
in Prevention: an Intervention Trial Evaluating Rosuvastatin 
(JUPITER) became available.35 This study evaluated the 
effect of 20 mg of rosuvastatin daily in healthy men and 
women (8901 on active medication and 8901 in placebo 
group) with entry median LDL cholesterol of 108 mg/dL 
(untreated), but with elevated high speciﬁ  city C-reactive 
protein (HSCRP) (median 4.2 mg/L). Primary outcomes 
included non-fatal MI, non-fatal stroke, hospitalization for 
angina, arterial revascularization procedures, or conﬁ  rmed 
death from CVD causes. After median follow-up of 
1.9 years, the Steering Committee decided to stop the trial Vascular Health and Risk Management 2009:5 372
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on the recommendation of the Safety and Data Monitoring 
Board because of a signiﬁ  cant cardiovascular beneﬁ  t in the 
treated patients. Patients in the rosuvastatin group had a 44% 
reduction in primary end points (hazard ratio [HR] 0.56, 
95% CI 0.46–0.69, p  0.00001).35 Unlike the meta-analysis 
results,15,36 JUPITER showed more a pronounced reduction 
of cardiovascular hazard. For 1 mmol/L (38.7 mg/dL) of 
LDL cholesterol decrease there was almost twice as pre-
viously reported (∼20%) decline of vascular risk. In the 
Jupiter study, there was no difference in subgroup analysis 
in reduction of risk for CVD events, including subgroups 
evaluated by traditional risk factors and Framingham 
risk score.35 The results of the Jupiter study raise several 
important questions:
1.  Are currently recommended LDL cholesterol goals 
appropriate, particularly in primary prevention, or should 
they be substantially lowered?
2.  Do we need to set the lower standards for even healthy 
people with elevated HSCRP to achieve reduction of 
CVD events in primary prevention settings?
3.  Does HSCRP have any direct effect on the cardiovascular 
system, or is it just a marker of an inﬂ  ammatory state?
The Air Force/Texas Coronary Atherosclerosis Prevention 
Study (AFCAPS/TexCAPS)24,37 revealed that otherwise 
healthy patients with baseline LDL cholesterol less than 
3.89 mmol/L (150 mg/dL) and low HSCRP (less than 
1.6 mg/L) had no signiﬁ  cant CVD event reduction after a 
year of 20 mg/day lovastatin therapy. Overall, the effect of 
lovastatin therapy on HSCRP was about 15% reduction by 
the end of the 1-year treatment period; however, there was 
no correlation between LDL cholesterol and CRP reduction.37 
Other statins as well are associated with signiﬁ  cant reduction 
of HSCRP levels.38 In the meta-analysis39 of 23 studies 
with 57 treatment groups (58% statin-only group and 
23% ezetimide in combination with statin) the reduction 
of HSCRP depended on magnitude of LDL cholesterol 
reduction, rather than mode of reduction. According to 
Kinlay et al39 the relationship can be detected more easily 
in meta-analysis, since in smaller studies it can be diluted. 
The high correlation between changes in LDL cholesterol 
and CRP (r = 0.80, p  0.001) strongly support a causal 
link between changes in LDL cholesterol and arterial 
inﬂ  ammation in atherosclerosis.39 A recent longitudinal study 
reported that incorporation of HSCRP into the risk stratiﬁ  -
cation algorithm modestly improves detection of patients 
at higher risk, who otherwise would have been missed 
compared to the traditional risk assessment.40 An algorithm 
incorporating HSCRP and parental history improved risk 
prediction 5.3% overall and 14.2% for patients at intermedi-
ate risk by traditional risk scores (both p  0.001).40
There is a direct effect of statins (rosuvastatin, atorvas-
tatin, simvastatin and pravastatin) on CRP production by 
human hepatocytes.41–43
Statins not only lower LDL cholesterol, but have effects 
on the size and concentration of LDL particles. The study 
by Ai et al44 in 271 hyperlipidemic men and women showed 
signiﬁ  cant alteration of LDL cholesterol composition by 
maximal doses of rosuvastatin (40 mg/day) and atorvastatin 
(80 mg/dL). Rosuvastatin was more effective in reducing 
small dense LDL cholesterol over the course of 6 weeks 
(53% vs 46%, p  0.01).44 Both statins favorably affected 
the subpopulation of HDL particles.44
The recent Consensus Statement from the American 
Diabetes Association and the American College of 
Cardiology46,47 foundation examined several questions:
1.  To what extent do lipoproteins contribute to CVD?
2.  What are the clinically important lipoprotein parameters?
3.  What are the principles and objectives of treatment of 
lipoprotein abnormalities?
The statement addressed the issue of global cardio-
metabolic risk (GCMR). Factors contributing to the GCMR 
include genetics, age, lifestyle as well as the presence of 
insulin resistance syndrome, hypertension, abnormal lipids, 
pro-inﬂ  ammatory, and hypercoagulable states. The recom-
mendations included an assessment of GCMR followed 
by a multifactorial risk reduction strategy. In terms of 
dyslipoproteinemia, statin therapy was recommended 
for the majority of patients with GCMR. In patients with 
dyslipidemia, the evaluation of not only total and LDL 
cholesterol concentrations but non-HDL cholesterol, apoB 
concentration by means of direct measurement, or evalua-
tion of LDL particle number by nuclear magnetic resonance 
assay was suggested. Previously, several studies found that 
LDL particle numbers may be a better predictor of CVD 
events than LDL cholesterol or non-HDL cholesterol con-
centration.45 The ADA Consensus statement also suggested 
conducting “clinical trials to determine if pharmacological 
therapy required to achieve very low levels of atherogenic 
lipoproteins is safe and cost-effective.”  46,47
Slowing of the progression 
of atherosclerosis
The Reversal of Atherosclerosis with Aggressive Lipid 
Lowering (REVERSAL) study6 was the ﬁ  rst to indicate 
that statins may not only reduce the cholesterol level, 
but as well slow the progression of atheroma volume as Vascular Health and Risk Management 2009:5 373
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assessed by intravascular ultrasound (IVUS) examinations 
at baseline and after 18 months of treatment. IVUS provides 
a precise and reproducible method for determining the 
change in atheroma burden during treatment. Six hundred 
fifty-seven patients (502 completed the study) with 
mean LDL cholesterol of 3.89 mmol/L (150.2 mg/dL) 
were randomized to 40 mg of pravastatin or 80 mg of 
atorvastatin per day. The pravastatin group (n = 549) 
achieved LDL cholesterol reduction down to 2.85 mmol/L 
(110 mg/dL) and the atorvastatin group (n = 253) down 
to 2.05 mmol/L (79 mg/dL) (p  0.001). The percent-
age change in atheroma volume showed a progression of 
coronary atherosclerosis in the pravastatin group (2.7%; 
95% conﬁ  dence interval [CI], 0.2%–4.7%; p = 0.001) 
compared with baseline and absence of progression in the 
atorvastatin group (–0.4%; CI –2.4% to 1.5%; p = 0.98) 
compared with baseline.6
The Study to Evaluate the Effect of Rosuvastatin on 
Intravascular Ultrasound-Derived Coronary Atheroma 
Burden (ASTEROID trial)48 included 349 patients with at 
least one vessel with 20%–50% luminal narrowing in any 
coronary artery. Participants were treated with a 40-mg 
dose of rosuvastatin for 2 years. The initial median LDL 
cholesterol was 3.28 mmol/L (127 mg/dL) and during 
treatment 1.5 mmol/L (58 mg/dL), representing a 53.2% 
reduction from baseline (p  0.001). The ASTEROID trial 
reported regression of percent atheroma volume and total 
atheroma volume compared with the baseline (p  0.001 
for both); 63.6% of participants showed reduction of the 
percent atheroma volume. The ASTEROID authors also 
examined correlations between mean LDL cholesterol levels 
and median change in percent atheroma volume in several 
IVUS trials. A close correlation was observed (r2 = 0.97). The 
level at which percent atheroma volume was 0 corresponded 
to the LDL cholesterol level about 2.02 mmol/L (78 mg/dL). 
This suggests that to achieve clinically signiﬁ  cant reduction 
in cholesterol burden, a LDL cholesterol level of less than 
2.02 mmol/L (78 mg/dL) would need to be attained and 
sustained over time.48
IVUS is an expensive and invasive procedure associated 
with certain complications (such as bleeding, reaction to IV 
contrast) and therefore, currently, not a practical modality 
to use clinically for follow up on atheroma burden. Other 
modalities have been studied in order to evaluate the effect 
of statins on atherosclerosis progression. Measurement of 
carotid intima media thickness (cIMT) has proven to be a 
safe, but controversial method as a surrogate for coronary 
artery disease. The clinical trials ARBITER,49 METEOR,50,51 
ACADIM52 and SANDS53 have demonstrated the reduction 
of cIMT in both, high risk and low risk patients.54
Real life goal attainment
As reviewed above, cholesterol lowering with 3-hydroxy-
3-methylglutaryl–coenzyme A (HMG-CoA) reductase 
inhibitors reduces vascular events signiﬁ  cantly in primary 
and secondary prevention of CHD. But how does it trans-
late into a real life practice? Several studies have addressed 
this question. A European survey was conducted under 
the auspices of the European Society of Cardiology (ESC) 
to describe the treatment of hyperlipidemia among CHD 
patients in Europe.55 The ﬁ  rst EUROASPIRE survey took 
place in 1995 to 1996 and the second survey was carried out 
in 1999 to 2000 in 15 European countries and enrolled 8181 
patients with known CHD. Medical records were assessed at 
least 6 months (median time 1.4 years) after the CVD event 
and clinical examinations of risk factors including serum 
lipids were performed. While 89.2% of the whole cohort 
needed cholesterol-lowering medication, 68.3% received 
it, and of these only 50.6% achieved lipid-lowering goals. 
Of patients on lipid-lowering medications, statins were pre-
ferred and were used alone or in combination in 91.7% of 
patients. The results varied considerably between countries. 
The most frequently used doses of lipid-lowering agents 
were much lower than the doses of proven effective doses 
used in clinical trials.55,56 The 9 countries that participated 
in both EUROASPIRE I and II surveys showed that there 
had been a signiﬁ  cant increase in the proportion of patients 
reaching the total cholesterol goal 5.0 mmol/L. The 
number of subjects treated and at the total cholesterol goal 
increased from 21% to 49%.56 This is a great improvement, 
but leaves half the patients short of optimal cholesterol levels. 
A larger European observational trial, Return on Expenditure 
Achieved for Lipid Therapy (REALITY) included about 
58,000 patients, mostly from general practice ofﬁ  ces, from 
10 different countries.57 They were followed for an average of 
15.3 months between 1998 and 2001. About 89% of patients 
were started on statins, mostly at low doses and only 40.5% 
achieved the goal of total cholesterol 5.0 mmol/L. The 
important ﬁ  nding of this study was the poor goal achieve-
ment in high-risk patients with known CHD (less than 30%), 
which may indicate the presence of an intrinsically more 
complex lipid disorder, under-treatment, or a combination 
of both. Less than 20% patients had their doses titrated up 
even when they were not at the target, and even less were on 
combinational therapy. Interestingly, the goal attainment did 
not increase with statin potency. Atorvastatin was effective in Vascular Health and Risk Management 2009:5 374
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56.4% of subjects at its lowest dose of 10 mg daily and only 
6.7% in patients on 80 mg a day (Table 1). This was most 
likely due to more severe hypercholesterolemia in patients 
on a higher statin dose.57
As in clinical trial settings, in real life settings patients 
who achieved better cholesterol control had reduction of 
risk of hospitalization for CVD (p = 0.05). Among French 
patients, the incidence of CVD events was much less in 
patients who achieved the LDL cholesterol goal (5.5% vs 
12.9% of patients not at treatment goal during any of 3 years 
of observation, p = 0.01). In Sweden the risk of major CVD 
events was signiﬁ  cantly lower (24%) in patients who met the 
therapeutic target than in those who did not. Cardiovascular 
hospitalization cost was signiﬁ  cantly lower at 2 to 3 years 
for achievers vs non-achievers.57
More recent ﬁ  ndings from Italy indicate an increased use 
of statins when compared to all the prescriptions written in 
1994 to 2003.58 The prevalence of statin use increased from 
1.1% in 1994 to 4.35% in 2003. Importantly, only half the 
patients who started on statins continued on the medica-
tion after 1 year. The cohort of 10,890 Italian patients was 
evaluated for adherence to statin therapy. Among the subjects 
in the primary prevention group (n = 8681), 56% were taking 
statins less than half the time, and only 19% of patients were 
adherent to the regimen. In the secondary prevention group 
(n = 3209), 41% of patients took the medication more than 
80% of time (p  0.001). Younger people (less than 54 years) 
had worse compliance than patients older than 64 years 
(53% vs 46% respectively, p  0.001).58 However, this 
study did not address the causes of poor compliance or drug 
cessation. A Canadian study tried to evaluate different causes 
of discontinuation of statin therapy.59 Patients in primary pre-
vention rather than secondary prevention groups (HR 1.18; 
1.11–1.25) and older patients were more likely to continue 
the therapy than a younger cohort (HR 0.99; 0.98–0.99). 
Subjects with diabetes, hypertension, respiratory disease and 
on antidepressants and overall having a greater number of 
different classes of drugs (3) taken were less likely to stop 
the cholesterol lowering medications. The total number of 
daily drug doses (HR 1.18; 1.15–1.20) signiﬁ  cantly increases 
the rate of cessation.59
Female sex was associated with lower adherence than 
male sex. However, statins are class C during pregnancy 
and a feasible explanation is that younger women have less 
adherence to the medication while they are in child-bearing 
age. The concurrent use of birth control pill and HRT indeed 
increased the compliance to suggested statin doses according 
to this study’s results.
Subjects living in a rural environment (HR 0.89; 
0.85–0.94) were also less likely to cease their statin agents. 
Subjects receiving social assistance (HR 1.01; 0.96–1.07) 
were not associated with a better or lower cessation rate.
The factors that increase the chances of therapy cessation 
included use of multiple pharmacies or multiple prescribing 
physicians (HR 1.76; 1.65–1.89 and HR 1.77; 1.66–1.89 
respectively.59 However, this study did not address the issue 
of drug discontinuation due to adverse effects or ineffective-
ness. In clinical trials of statins, the drop out rate is generally 
around 3% to 9%, but clinical trial populations are usually 
much more closely selected and homogeneous than conven-
tional clinical practice cohorts.12,35,51
Pedan et al studied statin adherence in a US cohort, and 
detected that a higher co-pay and lower number of prescribed 
reﬁ  lls were likely to be associated with non-adherence.60 
Surprisingly, patients, who were given a 90-day supply (and 
therefore, most likely a 1-year reﬁ  ll) were excluded from 
this study. Physicians who prescribed less statins had higher 
patient adherence rates and pharmacies that dispensed more 
statins had better patient adherence. The authors speculated 
that physicians who wrote the most statin prescriptions were 
more likely to work in the primary care settings and therefore 
had less time to spend with patients, rather than specialists.60 
Unfortunately, this study did not have data on specialty of 
physicians included in the study.
Riesen et al tried to assess whether use of a compliance 
tool would improve the adherence to the rosuvastatin.51 
Compliance tools included: a) a starter pack for subjects 
containing a videotape, an educational leaﬂ  et, a passport/goal 
diary and details of the help-line and/or website; b) regular 
personalized letters to provide message reinforcement; 
c) a toll-free help-line and a website. The adherence in both 
interventional and control groups was very high (around 
97%–100%) and, therefore, intervention with compliance 
tools did not improve the clinical outcomes of LDL choles-
terol goal reduction.51 However, this was a clinical trial and 
not a real life situation and it would be interesting to have 
studies done including similar compliance kits to evaluate 
if this translates into improvement of statin adherence in 
real life settings.
Conclusion
Statins are safe and effective therapy for reduction of 
myocardial infarction, ischemic stroke, and peripheral 
vascular events in primary and secondary settings. The 
effect is more pronounced after sustained lipid lowering for 
1.5 to 2 years. Rosuvastatin appears to be the most effective Vascular Health and Risk Management 2009:5 375
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statin currently available on the market for lowering LDL 
cholesterol, and at higher doses, increases HDL cholesterol 
rather than decreases it, as is often the case for atorvastatin 
or simvastatin at the 80 mg level. Rosuvastatin was effective 
in reducing CVD events in healthy patients with currently 
“normal” levels of LDL cholesterol but high HSCRP.
Having safe and effective statins for LDL cholesterol 
lowering has the potential to substantially reduce cardiac and 
ischemic stroke event rates, but, in the clinical setting, the rate 
of statin discontinuation is very high and overall adherence 
to the medical regimen is low. To reduce discontinuation and 
improve adherence we would recommend the education of 
pharmacists, physicians and patients concerning persistence 
with treatment. At least 2 to 3 years of consistent LDL 
cholesterol lowering are needed to see signiﬁ  cant reduction 
in CVD events and atheroma burden.
Practical pearls
Provide more reﬁ  lls at the original prescription. Try to use 
a once-daily formulation.
Cheapest co-pay will be more likely associated with 
better adherence.
Work more closely with women and younger population 
in primary prevention settings for adherence.
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